Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
AbCellera Biologics Q1 Earnings Call Highlights
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says
What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
AbCellera Reports Full Year 2025 Business Results
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of “Hold” by Brokerages
AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL
AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of “Hold” by Analysts
AbCellera and Bruker Reach Global Settlement of Patent Litigation
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
AbCellera Reports Q3 2025 Business Results
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
AbCellera Biologics: Entering Growth Phase After A Pause
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy?
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
AbCellera to Participate at Upcoming Investor Conferences in September
AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575